Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model

In recent decades, chimeric antigen receptor (CAR)–engineered immune effector cells have demonstrated promising antileukemic activity. Nevertheless, their efficacy remains unsatisfactory on solid cancers, plausibly due to the influence of tumor microenvironments (TME). In a novel mouse cancer model...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wai Nam, So, Wing Yan, Harden, Sarah L., Fong, Shin Yie, Wong, Melissa Xin Yu, Tan, Wilson Wei Sheng, Tan, Sue Yee, Ong, Jessica Kai Lin, Rajarethinam, Ravisankar, Liu, Min, Cheng, Jia Ying, Suteja, Lisda, Yeong, Joe Poh Sheng, Iyer, N. Gopalakrishna, Lim, Darren Wan-Teck, Chen, Qingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683725/
https://www.ncbi.nlm.nih.gov/pubmed/36417514
http://dx.doi.org/10.1126/sciadv.add1187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683725/
https://www.ncbi.nlm.nih.gov/pubmed/36417514
http://dx.doi.org/10.1126/sciadv.add1187

Ejemplares similares